Aerosolized antibiotic therapy appears to have potential for targeted therapy to the airways and deep lung to prevent VAP in patients at high risk for this disease. The definition of that high-risk population is important if this model is to be successful. We are attempting to define susceptible patients by measuring the volume of airway secretions, which mirrors the inflammation milieu of the central airways. Elevated sputum volume is marked by heavy growth of pathogenic organisms and high levels of inflammatory cytokines. Large-scale clinical trials are necessary to define the usefulness of these surrogates in defining a targeted population and for assessing the potential of aerosolized antibiotic prophylactic therapy for preventing pneumonia and mortality. If successful, the aerosol approach may avoid systemic therapy and its associated complications.
BaranD, DachyA, KlasterskyJ.Concentration of gentamicin in bronchial secretions of children with cystic fibrosis or tracheostomy. Int J Clin Pharmacol Biochem1975;12(3):336–341.
2.
NolanG, MelvorP, LevisonH, FlemingPC, CoreyM, GoldR.Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin. J Pediatr1982;101(4):626–630.
3.
HodsonME, PenkethARL, BattenJC. Aerosol carbenicillin and gentamicin treatment of Pseudomonas aeruginosa infection in pa-tients with cystic fibrosis. Lancet1981;2(8256):1137–1139.
4.
StephensD, GareyN, IslesA, LevisonH, GoldR.Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis. Pediatr Infect Dis1983;2(3):209–211.
5.
RamseyBW, PepeMS, QuanJM, OttoKL, MontgomeryAB, Wil-liams-WarrenJ, et al. Intermittent administration of inhaled tobra-mycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled To-bramycin Study Group. N Engl J Med1999;340(1):23–30.
6.
BrownRB, KruseJA, CountsGW, RussellJA, ChristouNV, SandsML. Double-blind study of endotracheal tobramycin in the treatment of Gram-negative bacterial pneumonia. The Endotracheal Tobramy-cin Study Group. Antimicrob Agents Chemother1990;34(2):269–272.
7.
SmaldoneGC, O'RiordanTG. Aerosol deposition and clearance. In: WagnerHNJr. Principles of nuclear medicine, 2nd ed. Philadelphia: WB Saunders; 1995.
8.
Determinants of dose and response to inhaled therapeutic agents in asthma. In: SchleimerR, BusseW, O'ByrneP, editors. Inhaled glucocorticoids in asthma: mechanisms and clinical actions. New York: Marcel Dekker, 1997.
SmaldoneGC. Drug delivery via aerosol systems; concept of "aero-sol inhaled", J Aerosol Med1991;4(3):229–235.
11.
IlowiteJS, GorvoyJD, SmaldoneGC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis1987; 136(6):1445–1449.
12.
SmaldoneGC, PerryRJ, BennettWD, MessinaMS, ZwangJ, Ilow-iteJ.Interpretation of 24 hour lung retention' in studies of muco-ciliary clearance. J Aerosol Med1988;1:11–20.
13.
JohansonWGJr., PierceAK, SanfordJP, ThomasGD. Nosocomial respiratory infections with Gram-negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med1972;77(5): 701–706.
14.
PalmerLB. Bacterial colonization: pathogenesis and clinical signif-icance. In: NiedermanMS, editor. Clinics in chest medicine. Phila-delphia: WB Saunders; 1987.
15.
Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep1997 Jan 3;46(RR-1):1–79.
16.
LangerM, MosconiPM, CigadaM, MandellaM.Long-term respi-ratory support and risk of pneumonia in critically ill patients. Inten-sive Care Unit Group of Infection Control. Am Rev Respir Dis1989;140(2):302–305.
17.
FagonJY, ChastreJ, DomartY, TrouilletJL, PierreJ, DarneC, GibertC.Nosocomial pneumonia in patients receiving continuous mechanical ventilation: prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis1989;139(4):877–884.
18.
BassinAS, NiedermanMS. Prevention of ventilator-associated pneu-monia: an attainable goal? (review)Clin Chest Med1995;16(1):195–208.
19.
UnertlK, RuckdeschelG, SelbmannHK, JensenU, ForstH, LenhartFP, PeterK.Prevention of colonization and respiratory infection in long-term ventilated patients by local antimicrobial prophylaxis. In-tensive Care Med1987;13(2):106–113.
20.
StoutenbeekCP, van SaeneHFK, MirandaDR, ZandstraDF, Lan-grehrD.The effect of oropharyngeal decontamination using topical nonabsorbable antibiotics on the incidence of nosocomial respiratory tract infections in multiple trauma patients. J Trauma1987;27(4): 357–364.
21.
PuginJ, AukenthalerR, LewDP, SuterPM. Oropharyngeal decon-tamination decreases incidence of ventilator-associated pneumonia: a randomized, placebo controlled, double-blind clinical trial. JAMA1991;265(20):2704–2710.
22.
GastinneH, WolffM, DelatourF, FaurissonF, ChevretS.A con-trolled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Study Group on Selective Decontamination of the Digestive Tract. N Engl J Med1992;326(9):594–599.
23.
FerrerM, TorresA, GonzalezJ, Puigde la Bellacasa J, el-EbiaryM, RocaM, et al. Utility of selective digestive decontamination in me-chanically ventilated patients. Ann Intern Med1994;120(5):389–395.
24.
QuinioB, AlbanèseJ, Bues-CharbitM, ViviandX, MartinC.Se-lective decontamination of the digestive tract in multiple trauma patients: a prospective double-blind, randomized, placebo-controlled study. Chest1996;109(3):765–772.
25.
KlickJM, du MoulinGC, Hedley-WhyteJ, TeresD, BushnellLS, FeingoldDS. Prevention of Gram-negative bacillary pneumonia us-ing polymyxin aerosol as prophylaxis. II. Effect on the incidence of pneumonia in seriously ill patients. J Clin Invest1975;55(3):514–519.
26.
FeeleyTW, du MoulinGC, Hedley-WhyteJ, BushnellLS, GilbertJP, FeingoldDS. Aerosol polymyxin and pneumonia in seriously ill patients. N Engl J Med1975;293(10):471–475.
27.
KollefMH. The prevention of ventilator-associated pneumonia (re-view). N Engl J Med1999;340(8):627–634.
28.
FullerHD, DolovichMB, PosmituckG, PackWW, NewhouseMT. Pressurized aerosol versus jet aerosol delivery to mechanically ven-tilated patients: comparison of dose to the lungs. Am Rev Respir Dis1990;141(2):440–444.
29.
MacIntyreN, SilverRM, MillerCW, SchulerF, ColemanRE. Aero-sol delivery to intubated, mechanically ventilated patients. Crit Care Med1985;13(2):81–84.
30.
O'RiordanTG, GrecoMJ, SmaldoneGC. Nebulizer function during mechanical ventilation. Am Rev Respir Dis1992;145(5):1117–1122.
31.
O'RiordanTG, PalmerLB, SmaldoneGC. Aerosol deposition in mechanically ventilated patients: optimizing nebulizer delivery. Am J Respir Crit Care Med1994;149(1):214–219.
32.
DiotP, MorraL, SmaldoneGC. Albuterol delivery in a model of mechanical ventilation: comparison of metered-dose inhaler and neb-ulizer efficiency. Am J Respir Crit Care Med1995;152(4Pt 1): 1391–1394.
33.
CabahugCJ, McPeckM, PalmerLB, CucciaA, AtkinsHL, Smal-doneGC. Utility of technetium-99m-DTPA in determining regional ventilationJ Nucl Med1996;37(2):239–244.
34.
PalmerLB, SmaldoneGC, SimonSR, O'RiordanTG, CucciaA.Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med1998;26(1):31–39.
35.
PalmerLB, SmaldoneGC, SimonS, O'RiordanT, MorraL.Tra-cheal aspirates in long-term mechanically ventilated patients: a hu-man model of Gram-negative infection and airway inflammation. Chest1995;108(5):1326–1332.
36.
DiotP, MorraL, SmaldoneGC. Albuterol delivery in a model of mechanical ventilation: comparison of metered-dose inhaler and neb-ulizer efficiency. Am J Respir Crit Care Med1995;152(4Pt 1): 1391–1394.
37.
PalmerL, SmaldoneGC. Targeting pneumonia in the ICU: secretion volume (abstract). Am J Respir Crit Care Med2000;161(3)A92.
